Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons.

OBJECTIVE To understand better the barriers among orthopedic surgeons and primary care physicians in identifying and treating possible osteoporosis in patients hospitalized with a fragility fracture sustained spontaneously or from a fall no greater than standing height. METHODS A 1-page, 7-question survey was sent to 35 admitting orthopedic surgeons and 75 primary care physicians at a midwestern managed care organization in March 2001. Returned surveys were collected until 30 days had passed since the mailing. Primary care physicians were board-certified family practitioners and internal medicine physicians. All orthopedists were admitting surgeons in the hospital system. Responders were anonymous, and posted surveys were returned to the Orthopaedic Collaborative Practice office. The surveys were color-coded to separate responses from orthopedic surgeons and primary care physicians. RESULTS Thirty-one surveys were returned: 23 (31%) from primary care physicians and 8 (23%) from orthopedic surgeons. Survey respondents agreed that the responsibility for postfracture attention to nutritional needs, including calcium and vitamin D, rested with the primary care provider. When asked about barriers to recommending bone mineral density testing with dual energy x-ray absorptiometry, 9 primary care physicians (39%) thought this type of testing was unnecessary for treatment, and 4 primary care physicians (17%) thought a barrier was caused by patient frailty. Primary care physicians indicated that potential adverse effects of medication (n=14 [61%]) and cost of therapy (n=13 [57%]) were the main factors limiting treatment. When asked to identify the single most important barrier in treatment, 14 physicians (61%) indicated cost was the greatest deterrent. Twenty-one primary care physicians (91%) reported they would be more likely to treat a patient with osteoporosis if a safe medication with proven fracture risk reduction were available. Primary care physicians indicated they were more likely to treat independently living adults (n=12 [52%]) and women compared with men (n=15 [65%]). All orthopedic surgeons (n=8) were willing for all patients to be evaluated in consultation with a nurse practitioner. Primary care respondents were less apt to agree with a nurse practitioner referral (n=5 [22%]). Both primary care physicians (n=16 [70%]) and orthopedic surgeons (n=4 [50%]) agreed that there is a need for increased primary care education about managing osteoporosis in patients hospitalized with low-impact fracture. CONCLUSIONS Orthopedic surgeons were consistent in their opinion that postfracture attention to osteoporosis should rest with the primary care physician. Primary care physicians agree but report that cost and possible adverse effects of medication are major barriers to this care. Despite therapies for high-risk postfracture patients showing relative safety and proven efficacy in reducing future fractures, deterrents to this care are focused on cost and potential adverse effects. Further education is needed to promote a standard of care for the postfracture patient that is directed toward the prevention of a subsequent fracture.

[1]  S. Bonnick Monitoring osteoporosis therapy with bone densitometry: a vital tool or regression toward mediocrity? , 2000, The Journal of clinical endocrinology and metabolism.

[2]  O. Johnell,et al.  Cost-Effectiveness of Preventing Hip Fracture in the General Female Population , 2001, Osteoporosis International.

[3]  S. Boonen,et al.  The Economic Cost of Hip Fractures Among Elderly Women: A One-Year, Prospective, Observational Cohort Study with Matched-Pair Analysis , 2001, The Journal of bone and joint surgery. American volume.

[4]  S. Adami,et al.  Alendronate for the Treatment of Osteoporosis in Men , 2001, Calcified Tissue International.

[5]  D. Hosking,et al.  Colles' Fracture of the Wrist as an Indicator of Underlying Osteoporosis in Postmenopausal Women: A Prospective Study of Bone Mineral Density and Bone Turnover Rate , 1998, Osteoporosis International.

[6]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[7]  O Johnell,et al.  How well can a previous fracture indicate a new fracture? A questionnaire study of 29,802 postmenopausal women. , 1998, Acta orthopaedica Scandinavica.

[8]  E L Hannan,et al.  Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. , 2001, JAMA.

[9]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[10]  P. Benum,et al.  Colles' fracture as an indicator of increased risk of hip fracture. An epidemiological study. , 1987, Annales chirurgiae et gynaecologiae.

[11]  R. Rizzoli,et al.  Weekly administration of alendronate: rationale and plan for clinical assessment. , 2000, Clinical therapeutics.

[12]  J. Berlin,et al.  Effect of testosterone treatment on bone mineral density in men over 65 years of age. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  G E Dallal,et al.  Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.

[14]  D. Kiel,et al.  Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis , 2000, Aging.

[15]  J A Stevens,et al.  Reducing falls and resulting hip fractures among older women. , 2000, Home care provider.

[16]  T. Abbott,et al.  Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  Mark A Pereira,et al.  Physical Activity, Falls, and Fractures Among Older Adults: A Review of the Epidemiologic Evidence , 2000, Journal of the American Geriatrics Society.

[18]  S. Cummings,et al.  Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. , 1999, Arthritis and rheumatism.

[19]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[20]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[21]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[22]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[23]  E. E. Hajcsar,et al.  Investigation and treatment of osteoporosis in patients with fragility fractures. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  E. Barrett-Connor,et al.  Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. , 1997, Archives of internal medicine.

[25]  M. Erlandsen,et al.  Occurrence and incidence of the second hip fracture. , 1993, Clinical orthopaedics and related research.

[26]  D. Kiel,et al.  Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. , 2000 .

[27]  J. Bilezikian,et al.  Bone densitometry: the best way to detect osteoporosis and to monitor therapy. , 1999, The Journal of clinical endocrinology and metabolism.

[28]  J. Glowacki,et al.  Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. , 1999, JAMA.

[29]  P Kannus,et al.  Prevention of hip fracture in elderly people with use of a hip protector. , 2000, The New England journal of medicine.

[30]  Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. , 2000, The Journal of clinical endocrinology and metabolism.

[31]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[32]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[33]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[34]  M S Calvo,et al.  Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.